FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 360:311-312 January 15, 2009 Number 3 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear

(Frontiers of Radiation Therapy and Oncology. Vol. 41.) Edited by Lutz Moser, Martin Schostak, Kurt Miller, and Wolfgang Hinkelbein. 130 pp., illustrated. Basel, Switzerland, Karger, 2008. $126. ISBN 978-3-8055-8524-8 (cloth); 978-3-8055-8525-5 (e-book).

The appropriate treatment of prostate cancer continues to challenge researchers and clinicians. During the past decade, intensive screening for prostate-specific antigen has resulted in a dramatic rise in the number of cases that are diagnosed in the United States and Canada. As a result of this screening, most men who are diagnosed with prostate cancer in North America present with disease that is localized to the prostate. Testing for prostate-specific antigen has also increased in Europe, but to a much lesser degree. Many European governments do not support screening for prostate cancer as a public health policy. As a consequence, . . . [Full Text of this Article]

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.